{
    "organizations": [],
    "uuid": "485ceed0dd58c1acb0476d3a18f97ef7b62b0a8f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-neurovive-raises-about-sek-785-mil/brief-neurovive-raises-about-sek-78-5-million-in-rights-issue-idUSASO0003XZ",
    "ord_in_thread": 0,
    "title": "BRIEF-NeuroVive Raises About SEK 78.5 Million In Rights Issue",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 27 (Reuters) - NEUROVIVE PHARMACEUTICAL AB:\n* PRESS RELEASE - PREFERENTIAL RIGHTS ISSUE IN NEUROVIVE OVERSUBSCRIBED\n* RIGHTS ISSUE SUBSCRIBED TO ABOUT MSEK 81.9, CORRESPONDING TO SUBSCRIPTION RATIO OF ABOUT 104 PERCENT\n* GETS ABOUT MSEK 78.5 BEFORE ISSUE EXPENSES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-27T14:41:00.000+03:00",
    "crawled": "2018-04-28T12:36:45.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "neurovive",
        "pharmaceutical",
        "ab",
        "press",
        "release",
        "preferential",
        "right",
        "issue",
        "neurovive",
        "oversubscribed",
        "right",
        "issue",
        "subscribed",
        "msek",
        "corresponding",
        "subscription",
        "ratio",
        "percent",
        "get",
        "msek",
        "issue",
        "expense",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}